Pascal Deschatelets Sells 78,907 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total value of $3,341,711.45. Following the sale, the insider now owns 1,115,983 shares in the company, valued at $47,261,880.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pascal Deschatelets also recently made the following trade(s):

• On Monday, April 8th, Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19.

Apellis Pharmaceuticals Stock Up 0.5 %

Shares of Apellis Pharmaceuticals stock traded up $0.22 during trading hours on Thursday, reaching $42.52. The company’s stock had a trading volume of 1,060,508 shares, compared to its average volume of 1,574,182. The company has a market capitalization of $5.16 billion, a P/E ratio of -12.29 and a beta of 0.97. The stock’s fifty day simple moving average is $54.30 and its two-hundred day simple moving average is $57.42. Apellis Pharmaceuticals, Inc. has a one year low of $19.83 and a one year high of $94.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). The company had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The firm’s revenue was up 284.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.56) EPS. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.27 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on APLS. Oppenheimer increased their target price on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. UBS Group dropped their target price on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday. Wedbush cut their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. HC Wainwright reissued a “buy” rating and issued a $92.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $76.67.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of APLS. Commonwealth Equity Services LLC increased its stake in Apellis Pharmaceuticals by 48.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 6,922 shares of the company’s stock valued at $263,000 after buying an additional 2,263 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Apellis Pharmaceuticals by 0.8% during the third quarter. Bank of New York Mellon Corp now owns 360,287 shares of the company’s stock worth $13,705,000 after acquiring an additional 2,998 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Apellis Pharmaceuticals by 10.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,021 shares of the company’s stock worth $533,000 after purchasing an additional 1,310 shares during the last quarter. First Horizon Advisors Inc. grew its stake in Apellis Pharmaceuticals by 69.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after purchasing an additional 265 shares during the period. Finally, Assetmark Inc. increased its position in shares of Apellis Pharmaceuticals by 88.5% during the 3rd quarter. Assetmark Inc. now owns 11,369 shares of the company’s stock valued at $432,000 after purchasing an additional 5,339 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).